secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corvus Pharmaceuticals, Inc. (CRVS)
CIK:        0001626971
Form:       8-K
Filed at:   2021-11-01T23:59:59+00:00
Accession:  0001171843-21-007353
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corvus Q3 net loss $10.7M, cash $76.3M; mupadolimab trials enrolling
--------------------------------------------------------------------

- Net loss for Q3 2021 was $10.7M vs $9.8M in Q3 2020; R&D expenses $7.0M vs $6.6M.
- Cash, equivalents and marketable securities $76.3M at Sept 30, 2021, up $32.0M from Dec 31, 2020; FY 2021 cash burn guided ~$36M.
- Two Phase 1b/2 trials of mupadolimab + pembrolizumab enrolling: relapsed NSCLC (n=15) and HPV+ HNSCC (n=15); results expected 2022.
- Angel Pharma received IND approval in China for CPI-818 Phase 1/1b in T-cell lymphoma; trial to open early 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626971/000117184321007353/0001171843-21-007353-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626971/000117184321007353/f8k_110121.htm
  HTML page:      https://secwatch.observer/filing/0001171843-21-007353

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer